ILUVIEN continues to show positive results in Europe

by The Medical News • 2015/09/28 • 0 Comments

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K.

← BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration

VIDEO: Retinal specialist dicusses treatment options for DME →

Post navigation